More Business Briefs
- Business briefs: Pfizer, Novartis, Boehringer Ingelheim, Elsevier
- Business Briefs: inVentiv; Mylan; Royalty Pharma; Pfizer; Edelman
- Business briefs: Actavis, Bayer, Oramed, Elan
- Business briefs: Pfizer, BMS, CMS, Sanofi
- Business briefs: Bayer, FDA, Ranbaxy
The FDA approved Celgene’s Revlimid (lenalidomide) for the
treatment of patients with transfusion-dependent anemia due to low-
or intermediate-1-risk myelodysplastic syndromes associated with
abnormalities. According to a company news release, distribution of
lenalidomide is expected to begin in early 2006.
Astellas Pharma US said the FDA approved Vaprisol (conivaptan
hydrochloride injection), an arginine vasopressin antagonist for
the intravenous treatment of euvolemic hyponatremia in hospitalized
The FDA approved Bristol-Myers Squibb’s Orencia (abatacept), the
first selective modulator of a co-stimulatory signal required for
full T-cell activation, for the treatment of rheumatoid arthritis.
Data published in the January issue of Mayo Clinic Proceedings
showed that Requip (ropinirole HCl) tablets significantly improved
RLS symptoms. The study, entitled “TREAT RLS US (Therapy with
Ropinirole, Efficacy and Tolerability in Restless Legs Syndrome),” is the
largest US study to date of the treatment of RLS.
Novartis breast cancer drug Femara (letrozole) won a new indication
for preventing relapse after surgery in women past menopause who
have early breast cancer.The drug is already approved for use in
treating advanced breast cancer and for use after five years of
standard treatment with an older cancer drug, tamoxifen.